Compare · STEX vs TMDX
STEX vs TMDX
Side-by-side comparison of Streamex Corp. (STEX) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STEX and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.25B, about 36.8x STEX ($88.2M).
- STEX has been more active in the news (7 items in the past 4 weeks vs 5 for TMDX).
- TMDX has more recent analyst coverage (19 ratings vs 1 for STEX).
- Company
- Streamex Corp.
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $88.2M
- $3.25B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 7
- 5
- Recent ratings
- 1
- 19
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest STEX
- Streamex Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Streamex to Participate as Innovator Partner at the Real-World Asset Summit in Brooklyn, New York; CEO Henry McPhie to Join Panel on Commodities Tokenization on September 2, 2026
- Siebert Partners with tZERO to Give Access to Digital Securities to Its Customers
- Streamex Corp. Announces July 2026 Yield Dividend Distribution for GLDY
- Streamex Corp. Reports Second Quarter 2026 Financial Results
- Streamex Corp. filed SEC Form 8-K: Leadership Update
- Streamex Corp. to Report Second Quarter 2026 Results and Host Business & Corporate Update Call
- Streamex Corp. Releases Investor Video on the Platform Strategy and Growth Initiatives Featuring VP of Product and Design Kori Handy
- Streamex Corp. Details GLDY’s Liquidity Infrastructure; ~$12 Million in Seeded Liquidity Supports 24/7, 365 Instant Trading Across Multiple Institutional-Grade Venues
- Streamex Corp. Announces 24/7, 365 Instant Liquidity for GLDY Through Collaboration with Wintermute
Latest TMDX
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)